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Sary Swedish population-based incidence and mortality rates for cancer of the uterine cervix, both in
situ and invasive, during the period 1958 to 1981 were determined by means of a dynamic model. This new
approach describes without any preconceptions the development of the disease as a sequential process over
the stages cancer in situ, invasive cancer before and after diagnosis, and death. The strong disurbance of the
steady-state situation that occurred after the introduction of cytological mass screening in the early 1960s
permitted the use of a computerized identification technique. The whole natural history of cervical cancer
could thus be identified and described consistently, with the mutual compatibility between statistical data,
structure, parameters, and the states and flows between the states. The estimated age-specifc incidence of
cancer in situ increased rapidly to a maximum of 650 per 105 woman-years at the age of 30 years, after which
it declined, and that of invasive cancer to a maximum of 55 per 105 at the age of 43. The natural history of
cervical neoplasia did not differ appreciably between eight successive 5-year birth cohorts. The proportion of
cases of new cancer in situ that progressed to invasive cancer was 12.2%, with a mean duration of the in situ
stage in these cases of 13.3 years. The precinical phase of the invasive stage (without screening) lasted on
average about 4 years.
Cytological screening for cancer of the uterine cervix has
been widely performed throughout the western world since
the early 1960s (Canadian Task Force on Screening, 1976;
Bourne & Grove, 1983; Hakama et al., 1985; Duguid et al.,
1985; Pettersson et al., 1985; Robra et al., 1985; Liri et al.,
1987) and it is now generally accepted that the mortality rate
from cancer of the cervix has declined as a result of the
screening measures (Kessler, 1974; Bourne & Grove, 1983;
Duguid et al., 1985; Hakama et al., 1985; Pettersson et al.,
1985; Robra et al., 1985; IARC Working Group, 1986). This
conclusion, however, remained controversial during many
years for two major reasons, namely the lack of randomised
trials and the deficient knowledge about the natural history
of cervical neoplasia. It seems to be generally accepted that
invasive cancer of the uterine cervix is preceded in most or
all instances by a preinvasive (in situ) stage (Boyes et al.,
1982). Data on the age-specific incidence of cancer in situ are
largely lacking and there are only few and contradictory
estimates of the proportion of in situ cancers that actually
progress to the invasive form and of the time constants in
the evolution from preinvasive cancer to clinical diagnosis
(Kessler, 1974; Boyes et al., 1982; Knox, 1982). It is also
unknown whether these parameters are associated with the
woman's age.
Beyond its obvious interest from a tumour-biological point
of view, a clear picture of the natural history of cervical
neoplasia would probably facilitate cost-effective designing
of screening interventions and might eventually minimise
overtreatment of preinvasive cancers that otherwise would
not have progressed to an invasive stage. In most instances,
however, ethical constraints prohibit studies on the untreated
progress of premalignant and malignant diseases. Advance-
ment of knowledge in this area - which has even been
considered impossible (Kessler, 1974; Draper & Cook, 1983)
- therefore requires other approaches than those tradi-
tionally used in medical research (Knox, 1982). Examples of
such alternative approaches are simulation techniques
(Bigelow, 1975; Coppleson & Brown, 1975; Knox, 1975;
Barron et al., 1978; Eddy & Shwartz, 1982; Yu et al., 1982;
Habema et al., 1983, Parkin, 1985; Parkin & Moss, 1986).
From the field of control theory it is well known that the
parameters of a system can be calculated provided that its
structure is known and that the system is disturbed. In this
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study, the access to suitable simulation languages and mathe-
matical packages (Pugh, 1976; Wait & Clark, 1977; The
IMSL Library, 1982; Gustafsson, 1983) facilitated our
approach which consisted of the use of an identification
technique. In addition, favourable prerequisites were offered
in Sweden through the availability of reliable incidence
(Cancer Incidence in Sweden, 1960-1984) and mortality
(Causes of Death 1958-1981) rates for cancer of the uterine
cervix over a 24-year period for the entire population of
about four million women, and through the extensive screen-
ing programme that was introduced in Sweden during the
early 1960s (National Board of Health and Welfare, 1982).
The purpose of this study was to investigate the natural
history of cervical neoplasia in terms of the states cancer in
situ, preclinical invasive cancer and invasive cancer after
diagnosis, and death, and the flows to, between and from
these states. A dynamic model which describes how these
states and flows are related was constructed.
We have tried to facilitate the reading of this paper by
keeping the presentation of technical aspects at a minimum
and presenting them in appendices. Detailed information
may, however, be of decisive importance for a critical
assessment of the internal validity of the study. An extensive
methodological presentation is therefore available on request
(Gustafsson, 1986).
Badgoun and material
Cytological screening
Cytological screening for cervical cancer with Papanicolaou
smears started in Sweden in the early 1960s, and organised
population-based programmes were successively introduced
during the period 1%7-1973 (National Board of Health and
Welfare, 1982; Pettersson et al., 1985). Women aged 30-49
years were invited to undergo cytological screening at 4-year
intervals. The extent of the organised screening was limited,
however, and the rate of participation was low until the end
of the 1960s, with only about 9,000 examinations in 1%7.
The total annual number of smears - within and outside the
organised screening - then increased rapidly to about one
million in 1970 and thereafter (National Board of Health
and Welfare, 1982). Less than one-quarter of the smears
have been taken within the organised screening and the
remainder outside this scheme at hospitals and outpatient
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clinics (National Board of Health and Welfare, 1982). By all
these means, which are denoted 'screening measures' in the
following text, a large number of cases of cancer in situ have
been detected (Figure 1) and cured every year. This interven-
tion therefore constitutes a disturbance of a steady state
situation, resulting in a reduction in the number of cases of
diagnosed invasive cancer some years later, and eventually a
reduction in the number of deaths due to cervical cancer.
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Figme 1 The total annual number of cases of cancer in situ and
invasive cancers of the uterine cervix reported to the Swedish
Cancer Registry and of deaths due to cervical cancer reported to
the Death Registry during the period 1958-1981.
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Figre 2 The age-specific incidence rates of invasive cancer of
the uterine cervix during defined years.
The cancer registry
Sweden has a population-based cancer registry which has
been operating since 1958 (Cancer Incidence in Sweden,
1960-1984). It is obligatory for all physicians in hospitals
and other establishments for medical treatment in Sweden to
report to the National Cancer Registry all cases of diagnosed
cancer. In addition, pathologists and cytologists separately
report every cancer diagnosis based on surgically removed
tissues, biopsies, cytological specimens and autopsies to the
registry. This obligation to report also includes cancer in
situ of the cervix uteri. The frequency of underreporting
to the registry has been estimated to be 0.7% for cancers of
the female genital organs (Mattsson & Wallgren, 1984).
Swedish population-based mortality statistics, which are pub-
lished annually, cover the entire period of cancer registration
(Causes of Death, 1960-1983). The cancer registry is linked
annually to the death registry and the date and causes of
death are transferred.
Four types of statistical data, based on the entire Swedish
female population, were used and divided into 5-year age
groups and are presented for each year. Thus we have used
annual figures for the years 1958-1981 for calculating: (1)
the number of detected new cases of cancer in situ of the
cervix uten (Cancer Incidence in Sweden, 1960-1984); (2) the
number of detected new cases of invasive cancer of the
cervix (Cancer Incidence in Sweden, 1960-1984); (3) the
number of deaths due to cervical cancer (Causes of Death,
1960-1983); (4) the number of women of different ages
(National Central Bureau of Statistics, 1959-1983).
During the period 1958-1981 the total number of reported
cases of cancer in situ was 64,215, of invasive cancer 18,218
and of deaths due to cancer of the uterine cervix 6,990
(Figure 1). From the population statistics the number of
women at risk was calculated as the average of the number
at the beginning and at the end of each year.
The number of detected cases with cancer in situ and with
invasive cancer and the number ofdeaths per year are shown
in Figure 1. After the end of the 1960s the incidence of in
situ cases found at screening was about five times that of
invasive cases diagnosed before screening measures were
undertaken, showing that only a small proportion of the
cancer in situ cases progressed. The surplus number of
invasive cancer and the number of deaths per year are shown
detection at screening is also evident (Figure 1). The screen-
ing effects are illustrated by age in Figure 2, which shows a
successive reduction from 1965 to 1981 in the incidence of
invasive cancer between the ages of 30 and 65 years.
Methods
To analyse the dynamics from the healthy state via cancer in
situ and invasive cancer to death, we need (1) a structural
Figre 3 The natural history of cervical neoplasia as a compartmental model. Transitions between states (LO) take place by flows
(-), which are controlled by rate valves (X). All the flows have the dimension of number of cases per 105 women-years The flows
for which statistics are available from cancer and death registers are indicated by filled valves (L. Abbreviations and parameters
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description (model) of the natural history based on differen-
tial equations, (2) appropriate statistics describing this form
of cancer during a time period longer than the time con-
stants of the system and (3) an identification method to
calculate the unknown quantities of the model from the
statistical data.
Model structure
Cervical cancer evolves with time from the state of being
healthy or having dysplasia, via cancer in situ and invasive
cancer, to death. We have some branching flows from this
sequence of progression of the disease. Thus in situ cases
may progress, remain stationary, regress or be discovered at
screening and cured. Diagnosed invasive cases may also be
cured. The main conceptual evolution is now elaborated into
a dynamic, integrated, compartmental model (Figure 3 and
Appendix 2). The states (prevalences) are represented by
levels or numbers of cases per 105 women. They change only
as a result of flows (incidences), which are numbers of cases
per year and 105 women. Both states and flows vary with
time. The designations in Figure 3 are defined in Appendix I
and will be used in the following text in order to be exact
and avoid confusion.
The number of in situ cases that are detected (SCR) is
highly dependent on the extent of cytological screening, and
the true incidence of cancer in situ (INS) is unknown. The in
situ box has a more detailed inner structure than is shown in
Figure 3. After extensive studies, a three-box structure was
found to give the most appropriate description of the in situ
stage. These investigations are discussed further below.
Invasive cancers have a preclinical phase during which
nothing is known and registered and - after detection - a
clinical phase during which the woman is a patient and can
be followed up (Figure 3). In the absence of screening, most
diagnosed cervical neoplasms are in the invasive stage,
whereas during screening a much greater number of in situ
(SCR) than of invasive (DIAG+DIAGSCR) cancers are
detected. The incidence flows of invasive cancers that surface
clinically (DIAG) and those of such cancers that are detected
at screening (DIAGSCR) cannot be separated on the basis
of the statistics from the Cancer Registry (Cancer Incidence
in Sweden, 1960-1984). It is these invasive cancers which
were found earlier as a result of screening that cause the
'bump' in the invasive curve of Figure 1.
The model also includes a number of unknown para-
meters. These are the sojourn times: T1, T2 and T3 in the
states of IN SITU, INV PRECLIN and INV CLIN respecti-
vely, and the proportion (P) of new in situ lesions that
without therapeutic measures would become invasive, and
finally the proportion (Q) of patients with invasive cancer
who will die of cancer of the cervix uteri. These parameters
are also shown in Figure 3 and exactly defined in Appen-
dices I and 2.
Estimating these parameters gives a unique model by
which all the flows and states can easily be calculated.
Statistical preprocessing
Cohort data The original data, obtained from official
Swedish statistics (Causes of Death, 1960-1983; National
Central Bureau of Statistics, 1959-1983; Cancer Incidence in
Sweden, 1960-1984) for each year and each 5-year age group
were compiled and entered into matrices of in situ and
invasive diagnoses, death and population. For technical
reasons it was appropriate to divide the in situ and invasive
diagnoses and death matnrces by the population matrix and
multiply by 105, which meant that we got three age-specific
matrices. In this context we wanted to distort the infor-
mation as little as possible and obtain smoothed data that
were unbiased over time. For this reason a 3-year average
was used, creating a new matrix from the old one, where
each new value was obtained as:
This means that the three terms X(t - 1), X(t), and X(t+ 1) all
refer to the same age but are sampled in three consecutive
years.
In order to study the effects of screening, which com-
menced in Sweden in the mid-sixties, we chose to analyse the
eight 5-year birth cohorts born between 1904 and 1943. Of
these cohorts, the six youngest had been heavily exposed to
screening measures, whereas the two oldest had been only
slightly exposed. The eight cohorts were of ages 50-54, 45-
49 and so on in 1958, with the youngest 15-19 years old.
They represented about two million women, including totals
of 38,969 women with cancer in situ, 13,830 women with
invasive cancer and 4,784 deaths due to cancer of the uterine
cervix during the 24-year study penrod. As a result we now
had the necessary statistics, which we denote SCRSTAT for
diagnoses of cancer in situ, DIAGSTAT for diagnoses of
invasive cancer and MORTSTAT for mortality from cervical
cancer, expressed per 105 women-years as based on cohort
data. In Figure 4 the numbers of diagnoses of invasive
cancer from 1958 through 1981 are shown for the eight
cohorts of this study.
Steady-state references To calculate the way in which
screening affects the annual number of diagnosed cases of
invasive cancer and of deaths, information was required both
for the situation without and for that with screening. We
therefore first calculated, as references. the annual numbers
for the situation when the system was not disturbed by
screening measures.
Referencefor incidence rates It is evident from the incidence
rates of cancer in situ in the Cancer Registry that between
1958 and 1963 the degree of screening was insignificant
(Figure 1). Moreover, only few of those cases detected at
screening during 1964-1967 would otherwise have been
diagnosed as invasive cancer before 1968. Screening thus
affected the incidence rates of invasive cancer to only a
negligible extent between 1958 and 1967. The incidence rates
for invasive cancer (Figure 4) were then plotted against age
for each cohort during only the first 10-year period 1958-
1967 of no screening effects. This resulted in a diagram
where each year is represented by values from exactly two of
the 5-year cohorts. Connecting these two values of each year
gives the vertical bars of Figure 5. In this figure the reference
(DIAGREF) of age-specific incidence rates was constructed
and denoted with a solid line.
Reference for mortality rates In the same way as
DIAGREF (see above), a reference for mortality rates
(MORTREF) was derived from the mortality rates for the
cohorts (MORTSTAT) in 1958-1967.
Identification
The way in which screening measures affect the whole
system is illustrated in Figure 3. The reported cancer in situ
cases (SCR) were subtracted from the in situ box, resulting
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Fgwe 4 Incidence of invasive cancer expressed as annual rates
per 10' women by age and year of birth (birth cohorts). Xnc.(t)
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Figwe 5 Incidence rates of invasive cancer during 1958-1967.
The constructed reference (DIAGREF) is indicated by a solid
line.
in a reduction of the flow of diagnosed invasive cancers
(DIAG) which is lagging and dispersed in time. The magni-
tude of this reduction should be the difference between
DIAGREF and (DIAG +DIAGSCR). Still later the distur-
bance will influence the mortality rates by a magnitude of
MORTREF-MORT. This gives the opportunity to use
identification technique on the prediagnosis submodel to
estimate the parameters P, TI and T2 and the INS-function
in a least square sense, and on the post-diagnosis submodel
to estimate the parameters Q and T3. (For further descrip-
tion of identification, see Appendix 3).
Validation
The validation work with its many technical aspects has been
extensively presented by Gustafssf (1986) and is only
bnrefly discussed here. This work included a large number of
tests of various hypotheses, structures and methods of
investigation; various tools for data handling, modelling,
simulation and identification were also tested.
Structure Validation of the hypotheses concerning structure
referred to the evolution of the disease during the in situ
phase and consequently to the way in which the in situ
structure should be modelled. The knowledge available
about this phase was too vague to be used. After testing a
number of different inner structures of the in situ stage, a
third order description was chosen; this gave an overall
performance of the model which was in accordance with the
statistical data. This inner description of the in situ stage
complicated the modelling work concerning regression and
screening flows. Different assumptions about the proportions
of these flows that come from the three substages had to be
tested. However, it was shown that these different assump-
tions had a very minor effect on the performance of the
model (Gustafsson, 1986).
Data validation The statistics used in this study referred to
the whole female population in Sweden, which meant a large
number of cases. We considered the validity and complete-
ness of these data (Mattsson & Wallgren, 1984) to be high,
probably the best obtainable. In addition, all women can be
followed up over long periods of time through linkage to the
unique national registration number. The statistics for
screening, invasive diagnoses, deaths and population were
produced yearly for women divided into 5-year age groups,
which gave a resolution that was high enough for our
purposes.
When constructing the references for the situation without
screening measures, we used statistics for the years 1958-
1967 in spite of the fact that screening had commenced some
years earlier. We argued that until 1967 the effects would
have been negligible. To test this assumption we investigated
the passage over time of cases from SCR to DIAG and from
SCR to MORT, respectively (Figure 3). The results sup-
ported the assumption that screening effects were negligible
between 1958 and 1967 (Gustafsson, 1986).
Temporal trends In the identification of the effects of
screening measures, it was implicitly assumed that otherwise
the system would have remained in - or close to - a 'steady
state'. We therefore had to analyse the possible impact of
any incidence trends during the years 1958-1981. The assess-
ment of such trends was based on statistical data that were
not affected by screening, namely: (1) data from the years
1958-1967 when screening had not yet affected the DIAG
and MORT flows; (2) old birth cohorts who had never been
exposed to screening; and (3) young birth cohorts before the
onset of screening effects.
Among women younger than 70 years there was virtually
no change in the incidence of cervical cancer during the
period 1958-1967. Older birth cohorts, which were largely
uninfluenced by screening, displayed a negligible upward
trend during the period 1958-1981. A trend toward increased
age-specific incidence rates emerged for the youngest cohorts
- especially among cohorts younger than those included in
this study. The main result, however, was that it seemed
unlikely that any trend would have been of such an order as
to disturb significantly the parameter estimates (Gustafsson,
1986).
Results
Results from the prediagnosis sub-model
Parameters All the cohorts showed similar results, with
surprisingly small variations in the parameter estimates
(Table I). An important result is that the parameters P, TI
and T2 can be regarded as constants instead of functions of
age, at least for the ages of the studied cohorts. The
proportion P= 12.2% means that only about 12 cases out of
a hundred new cases of cancer in situ would have progressed
to invasive cancer if left untreated. The proportion of
progressive in situ cases among all prevalent ones was
estimated from the model to be 15-23. The average
duration of the detectable in situ stage (Tl) was estimated at
13.3 years and of the preclinical invasive phase (T2) at 3.9
years, giving TI +T2= 17.1 years (Table I).
It is not known whether invasive and in situ cancers are
discovered with the same sensitivity at a cytological investi-
gation. In the first approach we included the ratio of the
sensitivity in diagnosing invasive cancer (Si,) to the sensi-
tivity in diagnosing cancer in situ (Si,) in the loss function
(VI defined in Appendix 3). We then obtained values of this
ratio of between 0.95 and 2.52 for the different cohorts,
indicating that invasive cancers can be somewhat easier to
Table I Results of the parameter estimation of the prediagnosis
submodel. For definition of parameters. see text and Appendix I
Cohort Cohort P Ti T2 Ti + T2 Relative
number born (%) (years) (years) (years) deviation'
1 1939-43 14.7 12.1 7.8 19.9 4.9%
2 1934-38 10.8 11.8 2.7 14.5 8.7%
3 1929-33 11.0 11.9 3.2 15.1 5.0%
4 1924-28 12.4 12.3 3.1 15.5 2.5%
5 1919-23 12.7 12.6 3.1 15.7 3.2%
6 1914-18 12.6 13.6 3.8 17.4 2.5%
7 1909-13 11.6 14.1 5.6 19.7 3.2%
8 1904 08 11.6 17.8 1.7 19.5 4.1%
Total Mean 12.2 13.3 3.9 17.1 4.3%
+s.d. 1.3 2.0 1.9 2.3 2.0%
tThe 'relative deviation is the difference in the reduction
DIAG+DIAGSCR-DIAGSTAT divided by DIAGSTAT and gives
one measure ofhow well the estimated incidence DIAG+DIAGSCR
fits with the statistics DIAGSTAT.136 L. GUSTAFSSON & H.-O. ADAMI
detect than cases of cancer in situ. In a second step, the
complete identification process was repeated with defined
values for the ratio Si,.,/Si, in order to determine the
sensitivity of the other parameters for different values of this
ratio. The results shown in Table I are the mean values of
the parameters for Si,UYSi,/ equal to 1 and to 2 (correspond-
ing to 1.5). When the ratio was changed by ±0.5, P changed
by 0.1 percentage point and TI +T2 changed by 0.25 years.
The main effect was noted on the distribution between TI
and T2. When the ratio increased by 0.5, TI increased and
T2 decreased by half a year. In view of these marginal
effects, a ratio of 1.5 was used throughout this study.
Impulse response In a study of the natural history, we are
especially interested in the development of the disease from
becoming cancer in situ, via becoming invasive, to diagnosis,
when not disturbed by screening actions. Such a description,
independent of cohort and age, showing the development of
the disease over time, was easily obtained from the model
when the parameters P, Ti and T2 had been estimated. In
Figure 3, we may look at the part of the model commencing
with the INS flow and ending with the DLAG flow. With the
states of the prediagnosis models IN SITU and INV PRE-
CLIN empty, we start the process by instantly 'injecting' a
large number of new in situ cases (an impulse enters as INS
flow), and look at the thereby induced flows INV and DIAG
(the responses of the impulse) that appear during the
following decades.
A diagram showing the fraction of cases flowing through
INV and DIAG as a function of time is called an impulse
response and is presented in Figure 6. Only 12.2% of the
cases will ultimately progress to INV and DIAG. In Figure 6
the cumulated fraction is also shown, where 100% represents
all of the progressing cases. From this figure mean, median
and peak values can also be obtained. The standard devi-
ation for the INV distribution is 7.6 years and for the DIAG
distribution 8.5 years. These estimates are implicitly deter-
mined by the selection of the model structure (see under
validation) and should have the correct magnitude but
should not be regarded as exact estimates.
The impulse response can be interpreted in terms of the
probability that one case entering cancer in situ wiHl appear
at [NV or DIAG a certain number of years later. The
probability that a new in situ case will become invasive
within 11 years is thus 50% under the condition that this
case will progress, and Px50%=6.1% for an unspecified
case to do this within this length of time.
Incidence rates of cancer in situ One aim was to estimate
the flow of new cancer in situ cases per year and 105 women.
This incidence is not affected by screening, which means that
when the model is fed with the flow of new in situ cases
(INS in Figure 3) and no screening measures are taken, the
number of diagnoses of invasive cancer will be equal to the
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Fuwe 6 Impulse response of the model showing the distribu-
tion of the duration of the in situ stage (denoted INV) and the in
situ plus preclinical invasive stage (denoted DIAG) (left scale)
and their cumulated values (right scale).
reference obtained from incidence rates before screening
(DIAGREF).
The calculated age-specific incidence of cancer in situ is
illustrated in Figure 7. The incidence increased rapidly
during the third decade of life, reached a maximum of 650
per 105 woman-years at the age of 30, and then gradually
declined to about 240 at the age of menopause (Figure 7).
Note that this calculation can only be strictly performed up
to the age of about 50 years, since the system was not
disturbed by mass screening above that age. However, for
ages over 50, the incidence of cancer in situ was estimated on
the assumption that the parameters which characterise
tumour progression (P, TI and T2) have the same values at
those ages as for lower ones. The part of INS over the age
of 50 is marked with a dashed line in Figure 7.
Results from the post-diagnosis sub-model
Without screening By driving the model with the incidence
rates of invasive cancer before screening (DIAGREF) to get
the estimated mortahity rate (MORT) as close as possible to
the mortality before screening (MORTREF), the parameter
values given in Table H were obtained. The relative devi-
ation is the difference between MORT and MORTREF
divided by MORTREF. The analysis revealed that the
proportion of patients who died of cancer of the uterine
cervix was relatively stable at a level of 33% until the age of
about 55 years (TQI). After this age, Q increased by about
2% per year.
With screening In order to obtain the post-diagnosis para-
meters by identification of the cohorts, the same procedure
as for the prediagnosis identification was carried out. As
input, the optimal DIAG and DIAGSCR from the prediag-
nosis identification were used. The opfimisation process for
minimising MORT-MORTSTAT for each cohort gave the
results presented in Table Ill.
The mortality fraction (Q) works well as a constant up to
the age of about 55, but thereafter it increases with increas-
ing age - as in the case without screening (see above). A QO
value of 33% seems to be a good estimate for all cohorts.
Ql and TQI are of course related. The lower the age of TQI
the smaller the value of Q1, and vice versa. The cohort
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Fugwe 7 Age-specific incidence rates of new cases of cancer in
situ of the uterine cervix. The dashed line above the age of 50
means that this part of the curve is based on the assumption that
the parameters P and TI +T2 are constants also for ages above
50.
Table I Parameter estimation for the post-diagnosis sub-model
without screening. For definition of parameters, see text and Appen-
dix I
QJ
DIAGREF--.MORT QO (% per TQI T3 Relative
VERSUS MORTREF (%) year) (vear) (years) deviation
Value 32.9 2.0 56 5.0 3.3%
Q=QO for age <TQI and Q=QO+Q1 (age-TQ1) for age>TQl.
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identification is not very sensitive in separating these two
parameters. However, the mean value agrees well with the
results of the sub-study without screening (above) - which
gives a more robust identification of Qi and TQI. It is
therefore concluded, mostly on the basis of the sub-study
without screening, that TQI=55+4 years, Q1=2.0+0.5%
per year and T3=4+2 years. (T3 is for technical reasons
hard to identify and for the older cohorts unidentifiable.)
The prognosis might differ between invasive cases diag-
nosed clinically and those diagnosed at screening. A constant
(L in Appendix 2) was therefore used and given values
between zero (which implied that no invasive cases detected
at screening would die) and I (which indicated that the same
proportion of cases diagnosed clinically and at screening
died of cancer of the cervix). In this study the value 0.5 was
used. A sensitivity test showed that Q and T3 decrease when
this constant increases, while Ql and TQI are very little
affected. For the unrealistic extreme assumptions 0 and 1, T3
changes by about one year and QO by about 0.03. The
influence on the estimates in Table HI was therefore con-
sidered to be small.
Discussion
Method
The natural history is a dynamic process which therefore
ought to be described by a dynamic model. This means that
the model has to be based on a system of differential
equations. While the model is non-linear and, for example,
its input flows of new in situ cases and of screening findings
are given by empirical data, it is practical to use a simulation
package to solve the system of equations over time. This
does not mean that this is a simulation study in the sense
that a simulation model based on various assumptions for
experiments or predictions is used as in most previous
studies (Coppleson & Brown, 1975; Knox, 1975; Yu et al.,
1982; Parkin, 1985; Parkin & Moss, 1986). In this study we
only used a simulation package to solve the differential
equations. Thus all the parameters, including degree of
regression, were uniquely calculated by comparison with
known statistics. In most Markov models the number of
parameters is much higher than that obtainable from statisti-
cal data. Statistical models, on the other hand, often fail
because they neglect the dynamic aspects. Many models also
assume that the degree of regression from cancer in situ to
normal is zero.
Our main task was to compare the behaviour of the
model, with its given structure and unknown parameters,
with the real behaviour described by incidence and mortality
time series for various cohorts. By using an identification
technique, known as parameter estimation, the set of para-
meters giving the best fit of the model behaviour to the real
TaMe HI Results of the parameter estimation for the post-
diagnosis sub-model with screening. For definition of parameters, see
text and Appendix 1
Ql
Cohort Cohort QO (% per TQJ T3 Relative
nwnber borm (%) year) (year) (years) deviation
1 1939-43 30.1 - - (0.7) 13.4%
2 1934-38 27.6 - - 2.6 13.1%
3 1929-33 34.2 - - 3.1 7.1%
4 1924-28 33.1 - - 3.9 6.6%
5 1919-23 32.5 3.5 51.7 3.7 4.2%
6 1914-18 37.2 8.0 59.3 4.3%
7 1909-13 37.6 1.2 51.2 5.6%
8 1904-08 37.0 2.5 59.8 6.8%
Total Mean 33.6 - - 7.6%
(1-8) +s.d. 3.6 - - 3.6
Total Mean 36.0 3.8 55.5 5.2%
(5-8) +s.d. 2.4 3.0 4.7 1.2
'For the last three cohorts T3 is technically unidentifiable.
one was determined. This gave us a consistent model with
the parameters estimated from real data in a least square
sense. This model could then be used for various simulation
studies. Parameter estimation is a standard identification
technique which has been used in various sciences and in
technology for many years (Eykhoff, 1974; Box & Jenkins,
1970; Ljung, 1987), although we do not know of other such
studies in this specific area of medicine.
Our analysis was based solely on cases of cancer in situ
and invasive cervical neoplasia notified to the cancer registry
and on deaths due to this disease recorded in the death
registry. We were thus unable to estimate the natural course
of dysplastic changes not reported as cancer in situ or to
analyse the possible impact of different criteria for diagnosis
of dysplasia, cancer in situ and invasive cancer on the
parameter estimates. The pragmatic approach which the use
of registry data implies will, on the other hand, have
increased the external validity of the results as they pertain
to the whole of Sweden and take into account the variations
in diagnostic criteria between pathologists and cytologists.
Moreover, the estimates should be independent of the timing
and extent of the screening measures. In the context of
natural history analyses, screening offered only the necessary
prerequisites for application of identification techniques
through the disturbance of the steady state system.
Results
The conceptual description of the natural history of cervical
neoplasia as progressing from dysplasia to cancer in situ and
invasive cancer and eventually to death seems to be generally
accepted and uncontroversial (Canadian Task Force on
Screening, 1976; Barron et al., 1978; Koss, 1979). The
estimates of probabilities and transition times for sequential
progression from one stage to the next have varied widely,
however, and the resulting vague idea about the true inci-
dence and untreated progression of in situ lesions has
severely hampered a rational and cost-effective design of
population-based screening measures (Kessler, 1974; Knox,
1982; Hakama et al., 1985). The incidence of cancer in situ
has been calculated in only few studies (Dunn & Martin,
1%7, Bibbo et al., 1971; Albert, 1981; Boyes et al., 1982;
Parkin et al., 1982). Parkin et al. (1982) derived the incidence
rate of cancer in situ from the prevalence figures obtained at
a second investigation after a cytologically normal smear.
Such an estimate does not account for the new lesions that
regress to normal during the intervening period of time. This
might partly explain the considerably lower figure of 69 per
105 reported by Parkin et al. (1982) than by us. The working
hypothesis proposed in the British Columbia cohort study
(Boyes et al., 1982) that the incidence of cancer in situ
decreases rapidly after a peak at the age of 30-34 was largely
confirmed in our analysis.
It has been unanimously shown in all studied populations
- and was further emphasised by our data - that the
cumulative incidence of cancer in situ is much higher than
that of invasive cancer (Cancer Incidence in Sweden, 1960-
1984; Miller, 1982). This observation is consistent with the
low proportion (about 12%) of new in situ cases progressing
from preinvasive to invasive cancer found in this study and
the view that regression is an important part of the natural
history of cancer in situ (Boyes et al., 1982). It would be
interesting to compare this result to what is found from
other studies. It is, however, important to bear in mind that
our estimate for the proportion of new cases in situ that
progress to invasive cancer (which we found constant over
age) cannot be directly compared to the proportion of
prevalent in situ cases that progress. This last measure is of
course a function of the INS curve and thereby of age, and
also of the specific screening activity earlier applied to the
population under study. We have no possibility to calculate
the parameter P from previous studies. However, we can
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different circumstances. Thus, with no screening measures,
our study (with P= 12.2%) gives a proportion of prevalent
in situ cases that progress to invasive cancer typically in the
range of 15-23%.
This estimate is lower than in most previous publications.
Although the range has varied from 25 to 70% (Petersen,
1956; Thorn et al., 1975), it has been stated that progression
occurs in 60% (Boyes et al., 1962), in a substantial propor-
tion (Coppleson & Brown, 1974; Koss, 1979) or even in the
majority (Canadian Task Force on Screening, 1976; Albert,
1981) of untreated patients.
The probability of progression of new in situ cases was
virtually about the same at all ages in this study. The slightly
higher value in the youngest birth cohort (14.7%) was
probably not due to chance or to a differing natural history
in this group. A more likely explanation would be that the
increasing incidence of invasive cancer in younger birth
cohorts (Cook & Draper, 1984; Duguid et al., 1985) reflects
a similar trend for in situ lesions as well.
The duration ofthe stage between transition from cancer in
situ to invasive cancer is another controversial issue, the esti-
mated mean duration varying from 1 to 30 years (Boyes et al.,
1962; Fidler et al., 1968; Boyes & Worth, 1968; Kashgarian
& Dunn, 1970; Coppleson & Brown, 1975; Canadian Task
Force on Screening, 1976; Barron et al., 1978; Koss, 1979;
Albert, 1981). The approach used in this study to assess this
quantity has not to our knowledge been used before, but
more recent analyses based on different statistical techniques
(Barron et al., 1978) have often yielded estimates relatively
close to those obtained here, i.e. about 12-14 years (Table I).
The progression time from cancer in situ to invasive cancer
showed no trend in relation to the different birth cohorts.
The natural course thus seems to be largely unrelated to the
age at inception of the in situ stage, a conclusion that
contradicts previous claims of slower (Dunn, 1953; Ashley,
1966; Coppleson & Brown, 1975; Hakama & Pentinnen,
1981; Prorok, 1986) or more rapid (Paterson et al., 1984)
progression im younger women.
Development of invasive cancer de novo, i.e. without a
preceding in situ stage, has been considered rare or unlikely
(Canadian Task Force on Screening, 1976). In our model
this would correspond to a progression time (T1) that
approaches zero. The cumulative proportion of invasive
cancer cases derived from the impulse response (Figure 6)
actually suggested that very short progression times are
infrequent; in the order of 10% of the cumulative number of
invasive cancers developed within the first 5 years after
entering the preinvasive stage.
The close agreement between model results and statistics
does not support the postulated existence of two major types
of cancer of the cervix with a definitely differing natural
course (Bailar, 1961; Ashley, 1966; Albert, 1981; Hakama &
Penttinen, 1981).
Conclusion
An important conclusion from this study is that it is possible
to construct a consistent model which describes the behav-
iour of eight different cohorts regarding both diagnoses of
invasive cancer and deaths during a period of 24 years with
only one and the same driving function and with only a few
parameters. Furthermore, these parameters are virtually con-
stants, unrelated to the cohort, to time and - with the
exception of Q - to age. This means that we have captured
the natural history of cervical cancer, which has proved to
be surprisingly constant over both age and time.
This study was performed at Uppsala University Computing Centre
and was supported partly by grants from the Swedish Cancer
Society.
Appenix 1. Definitn and abbrevtions
Definition of quantities and abbreviations. All incidence rates
(flows) are given per 105 women-years and the prevaakln per
105 women. Screening measures' refer to all efforts, within or
outside organised screening programmes. The notations are
best understood in connection with Figure 3.
CURE is the flow of cured cases.
DEAD means that the patient has died of cancer of the
uterine cervix.
DIAG+DIAGSCR is the flow (incidence rate) of diagnosed
and reported cases of invasive cancer. The two flows
DIAG and DIAGSCR cannot be separated in the statis-
tics. In the model, however, DIAGSCR is the incidence
rate of invasive cancer diagnosed at an earlier time as a
result of screening measures.
DIAGREF is the number of diagnoses of invasive cancer
before screening measures had an effect. This reference is
based on the years 1958-1967.
DIAGSTAT is the incidence rate of cervical cancer reported
in the statistics.
HEALTHY means that the subjects have neither cancer in
situ nor invasive cancer.
INS is the incidence rate of new in situ cases that would be
reported to the cancer registry if they were investigated.
IN SITU is the prevalence of women who would be reported
as having cancer in situ if they were investigated. This
figure includes those who have entered through the INS
flow and who have not left through REG, SCR or INV
flows.
INV is the incidence rate of invasive cases according to the
way in which such cancers are defined in medical practice.
INV CLIN is the prevalence of diagnosed but not cured or
deceased cases of invasive cancer.
INV PRECLIN is the prevalence of preclinical invasive cases
that entered through the INV flow but have not yet
departed through the DIAG or DIAGSCR flows to
become clinical (patients).
MORT is the mortality rate in the model.
MORTREF is the mortality before screening measures had
an effect, based on the average of the years 1958-1967.
MORTSTAT is the mortality rate for cervical cancer
reported in the statistics.
P is the proportion of new in situ cases that without
therapeutic measures would become invasive.
Q is the proportion of patients with invasive cancer who will
die of cancer of the cervix uteri. Q is not a constant for all
ages. We therefore used the function Q=QO for age
CTQ1 and Q=QO+QI (age -TQ1) for age >TQ1.
Thus three parameters, QO, QI and TQ1, had to be
estimated.
REG is the regression from IN SITU to HEALTHY.
RELATIVE DEVIATION is the quotient obtained as the
difference between the figure esimated by the model and
the figure according to the statistics divided by the latter
figure.
SCR is the incidence rate of cancer in situ reported to the
cancer registry. All these cases are treated and accordingly
eliminated from the IN SITU box. SCR refers to all such
cases whether they are detected in special screening
programs or not (In this study SCR=SCRSTAT.)
SCRSTAT is the incidence rate of cancer in situ reported in
the statistics.
TI is the time constant of the in situ stage in those cases
which become invasive.
T2 is the time constant for the stage between inception and
the time of diagnosis of invasive cases.
T1+T2 is the total time constant from INS to DIAG.
T3 is the survival time after diagnosis for those patients who
will die of invasive cancer.
Appenix 2. Matatical esento of the model
The compartmental model is depicted in Figure 3. To give
the complete mathematical representation of the model, some
information must be added.NATURAL HISTORY OF CERVICAL NEOPLASIA 139
The IN SITU box of Figure 3 is represented by three
successive states (INSITUI, INSITU2, and INSITU3) from
which the flows of progression, regression and SCR depart.
The proportional constants of the progression flow and the
regression flow are denoted d= 1/D and r= 1/R respectively.
(The case with different constants for these three states was
also treated, but is not discussed here.) The parameters P
and TI in this study are then related to D and R by:
From here on we only model the dying fraction. An extra
state, INV DELAY, was introduced for the DIAGSCR-flow
in order to adjust for leadtime due to screening. The dying
part of INV CLIN (Figure 3) is denoted INV CLIN-M.
Finally, 3= 1/T3 is the proportion of [NV
will die each year.
With the notation:
CLIN-M that
{D=T1/(3 x>P)
R=Tl/(3 x(l-aP)
Let t2= 11T2 denote the proportion of INVASIVE cases that
are detected each year without screening measures. Q is a
function of age which gives the proportion of the DIAG flow
that will die of cervical cancer, while L x Q is the correspond-
ing function for the DIAGSCR flow, where L is a constant
between 0 (no DIAGSCR cases die) and 1 (the same
proportion of DIAGSCR cases as DIAG cases die). Thus:
rX1 INSITU
X2 INSITU2
X= INSITU3
X4 INV PRECLINI
X5 INV DELAY
LX6 LINV CLIN-M j
DIAG=Q x DIAG+(1-Q) x DIAG
DIAGSCR =L x Q x DIAGSCR+(I -L x Q) x DIAGSCR We can write (X denotes the time derivative of X):
X1 =(-rl-d) x XI
X2=d x XI
X3=
X4=
X5=
X6=
(-r2-d) x X2
dxX2 (-r3-d) x X3
dxX3 -t2xX4
-t2xX5
Qxt2xX4 t2xX5 -t3 x X6
INS-SCRI
-SCR2
-SCR3
-DIAGSCR
L xQ x DIAGSCR
If we regard the flows INS,SCRt, SCR2, SCR3 and
DIAGSCR as inputs, we can write:
INS-SCR1 -
-SCR2
U = - -SCR3 -DIAGSCR
Lx Q x DIAGSCR
L _ O
0 0 0
r2-d 0 0 0 0
d -r3-d 0 0 O
O d - t2 0 0 X+U
0 0 0 -t2 0
0 0 Q xt2 t2 t3l
DIAGSCR(time, cohort)=
=Z x SCRSTAT x X4/(S1 x Xl +S2 x X2+S3 x X3)
It is seen that for any values of S1, S2 and S3 the flows
SCRI, SCR2 and SCR3 add up to SCRSTAT, which means
that we have built a mechanism for distributing SCRSTAT
proportionally to the respective INSITU levels. Our first
assumption was that S =S2=S3= 1. Other assumptions
concerning the distribution of cases detected at screening
correspond to other values of the SI, S2 and S3 coefficients
and were also tested, but did not give any improvement and
the effects on the results were small.
We also assume that Z=Sm,/S, is a constant denoting
the ratio of the sensitivity of detecting an INVASIVE case to
that of detecting an IN SITU case in the screening process.
DIAGSR is the flow of invasive cases that are detected
earlier on account of screening measures. We suppose that
the number of such cases is proportional to the number of
undiagnosed invasive cases and to the number of screenings.
The input INS is estimated as a function which depends
only on the age of a cohort, i.e. INS(age) =tabulated
function.
The other inputs, although with negative signs, that affect
the model are the flows due to screening. They are:
SCRI(time, cohort) =
=S1 xSCRSTATxXl/(Sl xXl+S2xX2+S3xX3)
SCR2(time, cohort)=
=S2 x SCRSTAT x X2/(S1 x Xl +S2 x X2+S3 x X3)
SCR3(time, cohort) =
=S3 x SCRSTAT x X3/(Sl x X +S2 x X2 +S3 x X3)
Appedix 3. Idetifrtion
Identification is a large discipline which includes a number of
techniques for different kinds of models, i.e. regression analy-
sis for static model impulse response, frequency analysis,
correlation analysis for non-parametric dynamic models, or
least square, maximum likelihood oF extended Kalman filter-
ing for parametric dynamical models, and so on. It also
discusses choice of model structure, experimental conditions
like different ways of perturbing a system, validation tech-
niques, etc. For more information about identification, see
e.g. Eykhoff (1974), Box & Jenkins (1970) and Ljung (1987).
In this paper we have used a parametric dynamical model
of ordinary differential equation. Input (disturbance) is the
elimination of in situ cases by screening, and output is the
{P =(R/(D+R))3
Tl =3xDxR(D+R) or
then we have:
-rl-d
d -r
Xk= O O
O
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number of invasive diagnoses. Our purpose is to find the
model (including a set of parameters whose values are a
priori unknown) that in a least square sense best fits the
system behaviour known from statistical data. This identifi-
cation technique is often referred to as parameter estimation.
This process is illustrated in Figure 8. The difference in the
outputs from the system and the model (V) over T years of a
study is minimised in a least square sense as:
lT
min l=TJe2(t)dt,
or, in a discrete form, as:
min V=-TEe2(t)
where e(t) is the deviation between model output and
corresponding statistics.
Our task was to find the set of parameters which would
minimise the loss function V We then performed the identifi-
cation, first of the prediagnosis and then of the post-
diagnosis sub-model.
The first part was based on the course up to the diagnosis
of invasive cancer, and the second part was based on the
course from diagnosis of invasive cancer to death. In both
cases the analyses were made on each of the eight cohorts.
Identification of the prediagnosis sub-model
The prediagnosis part of the model (Figure 3) starts with the
flow of new in situ cases (INS) and of cases eliminated by
screening measures (SCR), and ends with diagnoses of inva-
sive cancer (DIAG and DIAGSCR). Our goal was to esti-
mate for each of the eight cohorts in the study the
proportion of new in situ lesions that progress to invasive
cancer (P), the time constants for cancer in situ (Ti) and for
preclinical invasive cancer (T2), and the flow of new cancer in
situ cases (INS). (For further explanation, see Appendix 1
and 2.)
With SCR as a negative input to the system and the
model, we wanted to compare the reduction of diagnoses of
invasive cases from the system and from the model (Figure
8). We then constructed a loss function (V1) which measured
the difference between the system and model as a function of
P, Ti, T2 and INS.
1 1981
Vl=-- E ((DIAG+DIAGSCR)-DIAGSTAT)2
1958
LSCtR L SYSTEM IG - -SCR ~~~DIAGREAT D AGSTAT o1(-D)DiAG+DAGSCR
-DIAGSTAT
Output:
DLAGREF-
/DiAG.DIAGSCR)
P T1 T2 INS
Fugwe 8 The identification process for the prediagnosis sub-
model - a search for the parameter set which minimises the
difference between system (described by available statistics) and
model outputs. In the post-diagnosis sub-model the parameters
Q and T3 were identified accordingly by minimising
e2(t)=MORT-MORTSTAT.
measures this difference in a least square sense. We are then
searching for the combination of parameters P, T1 and T2
and an INS function that will mi niise V1. This latter is an
optimisation problem, which requires some hundreds of
simulation runs per cohort in order to obtain accurate
estimates of the parameters and the INS function.
Identification of the post-diagnosis sub-model
This part of the system - starting with the diagnosis of
invasive cancer and ending with death - could also have
been studied by using individual statistics for all patients and
calculating the fraction of mortality and the mortality time
constant directly. However, it was desirable to perform the
whole analysis in a consistent way. Our goal here was to
estimate the proportion of diagnosed invasive cases that will
die (Q) and the time constant from diagnosis to death (T3).
However, it was soon found that Q can be regarded as a
constant (QO) only up to a certain age (TQ1). After this age,
an annual increase, Ql, has to be added (see Appendix 1).
The quantities Q and T3 can be identified both for the case
without and the case with screening.
Technically the estimation of Q and T3 was performed by
iinimising the loss function V2 to get the best least square
fit between the system and model. Thus:
1 1981
min V2= - E (MORT-MORTSTAT)2
Q,T3 24 1958
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